ArticleBMC ophthalmology2026
A novel NYX gene mutation identified in a Chinese Northeast Han family with high myopia and night blindness.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study aimed to investigate the pathogenic gene mutation associated with high myopia and congenital stationary night blindness (CSNB) in a family from Northeast China. The objective was to clarify the underlying genetic basis and to determine the inheritance pattern of these ocular disorders.
methodsWhole-exome sequencing was performed on the proband using the NovaSeq 6000 platform. Variants were filtered based on an allele frequency of less than 0.5% in the gnomAD database. Their pathogenic was evaluated using multiple in silico prediction tools, including CADD, REVEL, SpliceAI, SIFT, MutationTaster, PolyPhen-2, and AlphaMissense. The identified NYX mutation was subsequently validated through Sanger sequencing in the proband and six additional family members. In addition, comprehensive clinical evaluations were conducted. These included detailed ophthalmic examinations, assessment of refractive status, and fundus imaging. These investigations were performed to characterize the phenotypic features and to establish correlations with the genetic findings.
resultsA novel frameshift mutation, c.264dup p. (Arf89Alafs *26), was identified in exon 3 of the NYX gene. The proband exhibited extremely high myopia, with a spherical equivalent of less than - 23.00D. This condition was accompanied by typical clinical features of CSNB. Structural analysis indicated significant conformational changes in the mutant protein. Pedigree analysis supported an X-linked recessive mode of inheritance. This pattern was consistent with both the clinical presentation and the genetic findings observed in the affected family.
conclusionThis study is the first to identify the NYX c.264dup mutation as a causative variant of complete CSNB (cCSNB) accompanied by extreme high myopia. This finding expands the known mutational spectrum of the NYX gene. These results provide valuable evidence for improving molecular diagnostic strategies. They also offer important support for more accurate genetic counseling in affected individuals and their families.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.